iRhythm Technologies
Market Cap
US$7.3b
Last Updated
2021/01/24 00:46 UTC
Data Sources
Company Financials +
Executive Summary
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Similar Companies
Share Price & News
How has iRhythm Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IRTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IRTC's weekly volatility (11%) has been stable over the past year.
Market Performance
7 Day Return
0.9%
IRTC
0.5%
US Medical Equipment
2.3%
US Market
1 Year Return
185.2%
IRTC
20.7%
US Medical Equipment
23.7%
US Market
Return vs Industry: IRTC exceeded the US Medical Equipment industry which returned 20.7% over the past year.
Return vs Market: IRTC exceeded the US Market which returned 23.7% over the past year.
Shareholder returns
| IRTC | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.9% | 0.5% | 2.3% |
| 30 Day | 4.4% | 3.9% | 4.7% |
| 90 Day | 14.8% | 7.2% | 14.5% |
| 1 Year | 185.2%185.2% | 21.7%20.7% | 26.5%23.7% |
| 3 Year | 313.7%313.7% | 64.5%60.4% | 45.0%35.4% |
| 5 Year | n/a | 166.7%146.9% | 126.2%100.9% |
Long-Term Price Volatility Vs. Market
How volatile is iRhythm Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
How Much Are iRhythm Technologies, Inc. (NASDAQ:IRTC) Insiders Taking Off The Table?1 month ago | Simply Wall St
A Quick Analysis On iRhythm Technologies' (NASDAQ:IRTC) CEO Salary2 months ago | Simply Wall St
When Will iRhythm Technologies, Inc. (NASDAQ:IRTC) Become Profitable?Valuation
Is iRhythm Technologies undervalued compared to its fair value and its price relative to the market?
21.8x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: IRTC ($252.74) is trading above our estimate of fair value ($124.42)
Significantly Below Fair Value: IRTC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IRTC is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: IRTC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IRTC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IRTC is overvalued based on its PB Ratio (21.8x) compared to the US Medical Equipment industry average (5.7x).
Next Steps
Future Growth
How is iRhythm Technologies forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
78.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IRTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IRTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IRTC's revenue (26.9% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: IRTC's revenue (26.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IRTC's Return on Equity is forecast to be low in 3 years time (1.5%).
Next Steps
Past Performance
How has iRhythm Technologies performed over the past 5 years?
-24.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IRTC is currently unprofitable.
Growing Profit Margin: IRTC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IRTC is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare IRTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IRTC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: IRTC has a negative Return on Equity (-15.39%), as it is currently unprofitable.
Next Steps
Financial Health
How is iRhythm Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: IRTC's short term assets ($365.9M) exceed its short term liabilities ($55.9M).
Long Term Liabilities: IRTC's short term assets ($365.9M) exceed its long term liabilities ($106.8M).
Debt to Equity History and Analysis
Debt Level: IRTC's debt to equity ratio (10.4%) is considered satisfactory.
Reducing Debt: IRTC's debt to equity ratio has reduced from 125.8% to 10.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IRTC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IRTC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is iRhythm Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IRTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IRTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IRTC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IRTC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IRTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.6yrs
Average management tenure
CEO
Mike Coyle (58 yo)
no data
Tenure
Mr. Michael J. Coyle, also known as Mike, has been President, Chief Executive Officer and Director of iRhythm Technologies, Inc. since January 12, 2021. Mr. Coyle serves as an Independent Director at Haemo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Vice President of Sales | 7yrs | US$1.80m | 0.077% $ 5.6m | |
| Executive Vice President of Research & Development | 9yrs | US$1.44m | 0.10% $ 7.6m | |
| Advisor & Director | 8.5yrs | US$4.77m | 0.66% $ 48.5m | |
| 0.58yr | US$1.93m | 0.030% $ 2.2m | ||
| President | no data | no data | no data | |
| CFO & Secretary | 0.58yr | no data | no data | |
| Executive Vice President of Strategy | 1.58yrs | no data | no data | |
| Executive Vice President of Marketing | 5.5yrs | no data | no data | |
| Vice President of Human Resources | 5.83yrs | no data | no data | |
| Chief Clinical Officer & Executive VP of Operations | 2.5yrs | no data | no data | |
| Executive Vice President of Information Technology & Customer Service | no data | no data | no data | |
| Executive Vice President of Payer Relations and Market Access | 3.58yrs | no data | no data |
3.6yrs
Average Tenure
56yo
Average Age
Experienced Management: IRTC's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Advisor & Director | 8.5yrs | US$4.77m | 0.66% $ 48.5m | |
| President | no data | no data | no data | |
| Independent Director | 7.08yrs | US$175.99k | 0.0061% $ 445.8k | |
| Independent Director | 3.5yrs | US$167.99k | 0.015% $ 1.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.5yrs | US$174.99k | 0.016% $ 1.2m | |
| Independent Chairman | 4.67yrs | US$217.99k | 0.016% $ 1.2m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.75yrs | US$165.99k | 0.0036% $ 262.7k | |
| Independent Director | 4.83yrs | US$179.99k | 0.016% $ 1.2m | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.7yrs
Average Tenure
64yo
Average Age
Experienced Board: IRTC's board of directors are considered experienced (4.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.4%.
Top Shareholders
Company Information
iRhythm Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: iRhythm Technologies, Inc.
- Ticker: IRTC
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$7.297b
- Shares outstanding: 28.87m
- Website: https://www.iRhythmTech.com
Number of Employees
Location
- iRhythm Technologies, Inc.
- 699 8th Street
- Suite 600
- San Francisco
- California
- 94103
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IRTC | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Oct 2016 |
| I25 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2016 |
Biography
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/24 00:46 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.